**Name of Journal:** *World Journal of Clinical Oncology*

**Manuscript NO:** 65078

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series**

Buti S *et al*. Pazopanib in advanced non-clear cell renal carcinoma

Sebastiano Buti, Melissa Bersanelli, Francesco Massari, Ugo De Giorgi, Orazio Caffo, Gaetano Aurilio, Umberto Basso, Giacomo Carteni, Claudia Caserta, Luca Galli, Francesco Boccardo, Giuseppe Procopio, Gaetano Facchini, Giuseppe Fornarini, Alfredo Berruti, Elena Fea, Emanuele Naglieri, Fausto Petrelli, Roberto Iacovelli, Camillo Porta, Alessandra Mosca

**Sebastiano Buti, Melissa Bersanelli,** Medical Oncology Unit, University Hospital of Parma, Parma 43126, Italy

**Melissa Bersanelli,** Medicine and Surgery Department, University of Parma, Parma 43126, Italy

**Francesco Massari,** Division of Oncology, Policlinico Sant’Orsola-Malpighi Hospital, Bologna 40138, Italy

**Ugo De Giorgi,** Department of Oncology, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola 47014, Italy

**Orazio Caffo,** Department of Medical Oncology, Santa Chiara Hospital, Trento 38122, Italy

**Gaetano Aurilio,** Department of Medical Oncology, Division of Urogenital and Head and Neck Tumours, European Institute of Oncology IRCCS, Milan 20141, Italy

**Umberto Basso,** Medical Oncology Unit 3, Istituto Oncologico Veneto IOV IRCCS, Castelfranco Veneto, Padova 31033, Italy

**Giacomo Carteni,** Division of Oncology, Azienda Ospedaliera di Rilievo Nazionale A. Cardarelli, Napoli 80131, Italy

**Claudia Caserta,** Medical Oncology Unit, Azienda Ospedaliera S. Maria, Terni 05100, Italy

**Luca Galli,** Oncology Unit 2, University Hospital of Pisa, Pisa 56126, Italy

**Francesco Boccardo,** Academic Unit of Medical Oncology, IRCCS San Martino Polyclinic Hospital, Genova 16132, Italy

**Giuseppe Procopio,** Medical Oncology Genitourinary Section, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan 20133, Italy

**Gaetano Facchini,** Departmental Unit of Clinical and Experimental Uro-Andrologic Oncology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli 80131, Italy

**Giuseppe Fornarini,** Medical Oncology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Policlinico San Martino, Genova 16132, Italy

**Alfredo Berruti,** University of Brescia, ASST-Spedali Civili, Brescia, Brescia 25123, Italy

**Elena Fea,** Medical Oncology Unit, S Croce and Carle Teaching Hospital, Cuneo 12100, Italy

**Emanuele Naglieri,** Division of Medical Oncology, Istituto Tumori G Paolo II, IRCCS, Bari 70124, Italy

**Fausto Petrelli,** Medical Oncology Unit, ASST Bergamo Ovest, Treviglio, Bergamo 24047, Italy

**Roberto Iacovelli,** Medical Oncology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome 00161, Italy

**Camillo Porta,** Division of Oncology, AOU Consorziale Policlinico di Bari, Bari 70124, Italy

**Camillo Porta,** Department of Biomedical Sciences and Human Oncology, University of Bari "A.Moro", Bari 70124, Italy

**Alessandra Mosca,** Multidisciplinary Outpatient Oncology Clinic, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin 10060, Italy

**Author contributions:** All authors contributed to the data collection and manuscript revision.

**Corresponding author: Melissa Bersanelli, MD, Adjunct Professor, Postdoctoral Fellow, Staff Physician,** Medical Oncology Unit, University Hospital of Parma, Via Gramsci 14, Parma 43126, Italy. bersamel@libero.it

**Received:** February 27, 2021

**Revised:** May 18, 2021

**Accepted:** September 3, 2021

**Published online:**

**Abstract**

BACKGROUND

Non-clear cell (ncc) metastatic renal-cell carcinoma (RCC) has dismal results with standard systemic therapies and a generally worse prognosis when compared to its clear-cell counterpart. New systemic combination therapies have emerged for metastatic RCC (mRCC), but the pivotal phase III trials excluded patients with nccRCC, which constitute about 30% of metastatic RCC cases.

AIM

To provide a piece of real-life evidence on the use of pazopanib in this patient subgroup.

METHODS

The present study is a multicenter retrospective observational analysis aiming to assess the activity, efficacy, and safety of pazopanib as first-line therapy for advanced nccRCC patients treated in a real-life setting.

RESULTS

Overall, 48 patients were included. At the median follow-up of 40.6 mo, the objective response rate was 27.1%, the disease control rate was 83.3%, and the median progression-free survival and overall survival were 12.3 (95% confidence interval [CI]: 3.6-20.9) and 27.7 (95%CI: 18.2-37.1) mo, respectively. Grade 3 adverse events occurred in 20% of patients, and no grade 4 or 5 toxicities were found.

CONCLUSION

Pazopanib should be considered as a good first-line option for metastatic RCC with variant histology.

**Key Words:** Pazopanib; Non-clear cell; Kidney cancer; Renal-cell carcinoma; Variant histology; Tyrosine kinase inhibitors

Buti S, Bersanelli M, Massari F, De Giorgi U, Caffo O, Aurilio G, Basso U, Carteni G, Caserta C, Galli L, Boccardo F, Procopio G, Facchini G, Fornarini G, Berruti A, Fea E, Naglieri E, Petrelli F, Iacovelli R, Porta C, Mosca A. First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series. *World J Clin Oncol* 2021; In press

**Core Tip:** Non-clear cell metastatic renal-cell carcinoma (nccRCC) has dismal results with standard systemic therapies and a poor prognosis. Few therapeutic molecules have been explicitly tested in nccRCC patients. We retrospectively collected 48 advanced nccRCC patients treated with pazopanib in the first-line setting, offering promising findings of quite good response rate (27%), progression-free survival around 12 mo, and overall survival around 28 mo. In light of these results, we suggest that pazopanib can be a good treatment choice in this subgroup of patients, pending the results of ongoing clinical trials with new therapeutic combinations.

**INTRODUCTION**

Non-clear cell renal-cell carcinoma (nccRCC) represents a heterogeneous group of tumors with distinct genomic and metabolic features. Therefore, its clinical behavior can be benign to indolent and even highly malignant with high metastatic potential[1].

Of note, non-clear mRCC has dismal results with standard systemic therapies and a generally worse prognosis when compared to its clear-cell counterpart, as demonstrated in a large study by the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC), showing a worse overall survival (OS) for patients with nccRCC compared to ccRCC patients [12.8 mo (95%CI: 11.0-16.1) *vs* 22.3 mo (20.7-23.5)][2].

Recent advances have offered the availability of new systemic therapies for metastatic RCC (mRCC), such as immunotherapy-based combinations with the current recommendation in the first-line setting[3-6]. These combinations, all forecasting the use of anti-PD-1/PD-L1 immune checkpoint inhibitors (ICIs), have been investigated in phase III randomized clinical trials (RCTs) enrolling patients with clear-cell RCC (ccRCC) or at least a clear-cell component in the tumor histology. Nevertheless, conventional clear-cell RCC accounts for only 70% of renal cortical tumors that metastasize, preventing to provide evidence for 30% of mRCC patients still lacking indication for the most productive therapeutic solutions. About nccRCC, international guidelines still recommend that such patients should be preferentially referred to clinical trials.

The previous gold-standard first-line therapies for mRCC, represented by anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors (TKIs) used as a single agent, have been in part investigated in nccRCC patients. In particular, sunitinib was tested in two prospective trials (the ESPN trial and the ASPEN trial) initially planned to show the superiority of the mammalian target of rapamycin inhibitor everolimus over sunitinib as first-line therapy. Both studies, on the contrary, finally supported the use of sunitinib as a primary systemic approach in this population of patients[7,8]. On the other hand, other TKIs have been approved in the first-line setting for all-mRCC histologies, including the alternative with pazopanib, which demonstrated similar efficacy and even better safety profile when compared to sunitinib in randomized trials[9,10]. Nevertheless, little evidence is available about using this drug in nccRCC patients, with a consequent reluctance to prescription in clinical practice, notwithstanding the drug's good profile, also suitable for frail and elderly patients[11,12].

Given the unmet oncological need for evidence for the systemic approach to nccRCC, the present report of a retrospective multicenter case series aims to provide a piece of real-life evidence on the use of pazopanib in this patient subgroup.

**MATERIALS AND METHODS**

***Study population and setting***

The present study is a retrospective, observational analysis aiming to assess the activity, efficacy, and safety of pazopanib as first-line therapy for advanced nccRCC patients treated in a real-life setting at multiple Italian institutions. The principal inclusion criteria were the diagnosis of nccRCC, including papillary RCC (pRCC), chromophobe RCC (chRCC), RCC with Xp11 translocation, RCC with undefined histology, and mixed-histology RCC with mostly ncc component; receiving the first dose of pazopanib between June 2012 and June 2015; > 18 years old; measurable disease at the computed tomography (CT) scans performed according to clinical practice at the treating centers. Data were collected between February 2017 and February 2018.

***Study endpoints***

The primary objective was to assess the outcome of patients in terms of objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), OS, and tolerability as co-primary endpoints. PFS was defined as the time between pazopanib initiation and disease progression or death; OS was defined as the time between pazopanib initiation and death or the date of the last follow-up visit for alive patients; DCR as responses plus stable diseases. Objective responses (complete, CR; partial, PR; stable, SD; progressive disease, PD) were evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1)[13] and assessed every 2-3 mo according to clinical practice.

Treatment-related adverse events (TRAEs) were recorded as clinical practice according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0 (in use at the time of the study conduct)[14].

The characteristics of patients were collected, and their correlation with the outcome was explored.

The study was reviewed and approved by the Local Ethics Committee of Parma (Italy). All study participants provided informed written consent before study enrollment.

***Statistical analysis***

Descriptive statistics are used to summarize the data. PFS and OS were estimated using the Kaplan-Meier method with 95% confidence intervals (CI) and compared using the log-rank test. Univariate and multivariate analyses were performed by using Cox proportional hazards models. The comparison between categorical endpoints was performed using the chi-square test. Significance levels were set at a 0.05 value, and all *P* values were two-sided. SPSS Statistics 24.0 software (IBM Corporation, Armonk, NY, United States) was used to conduct the statistical analyses.

**RESULTS**

From January 2011 to January 2017, 48 consecutive patients were included in 20 Italian centers. The median follow-up was 40.6 mo (95%CI: 22.3-58.9). The characteristics of patients are reported in Table 1. The median age was 70 (range, 27-86) years, and most patients were male (75.0%). Fifteen patients (31.3%) had distant metastases at disease onset. The majority of patients had pRCC (50.0%) or chRCC (18.8%) as histology. Most patients had previously received nephrectomy (85.4%), and seven (14.6%) had metastasectomy. Thirty-seven patients (77.1%) had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0. All IMDC risk groups were represented in the study population.

The median duration of treatment was 9.1 (range, 0.6-52.5) mo, and eight patients (16.7%) were still receiving pazopanib at the time of the last follow-up. Twenty-eight patients (58.3%) received a second-line therapy (four received nivolumab and three cabozantinib).

In 17 cases (35.4%), the starting dose of pazopanib was primarily reduced because of the patient conditions (age and/or comorbidity): Ten patients started with 600 mg, and seven patients started with 400 mg. Secondary dose reductions or temporary treatment discontinuations due to TRAEs were required in 19 cases (39.6%), mainly due to grade (G) 3 hepatic toxicity, fatigue, and diarrhea. G3 TRAEs occurred in 20.8% of patients, G1-2 in 81.2%, and no G4 toxicity was observed (Table 2).

PR was achieved in 13 patients (27.1%), and no CR was observed. Twenty-seven patients (56.3%) obtained SD; the DCR was 83.3%, whereas six patients (12.5%) had PD as the best response (while 4.2% were not evaluable). Neither ORR nor DCR was significantly correlated with any of the following parameters: Sex, histology, grading, sarcomatoid component, initial pazopanib dose, ECOG PS, and IMDC risk group.

Most cases of primary refractory (PD as best response) were pRCC. Table 3 shows the responses according to the histology.

Median PFS and OS were 12.3 (95%CI: 3.6-20.9) and 27.7 (95%CI: 18.2-37.1) mo, respectively (Figure 1, Table 3).

In the univariate analysis, no factors (among sex, previous nephrectomy, histology, grading, metastatic disease at diagnosis, previous metastasectomy, IMDC risk group, ECOG PS, and initial pazopanib dose) were significantly associated with PFS. Conversely, factors significantly associated with a better OS were IMDC group (*P* = 0.011), previous nephrectomy (*P* = 0.002), previous metastasectomy (*P* = 0.008), absence of metastatic disease at diagnosis (*P* = 0.014), and subsequent therapy with cabozantinib or nivolumab (*P* = 0.049).

Notwithstanding the limit of multivariate analysis in such a small sample size, it was performed for OS, and only the absence of metastatic disease at diagnosis (hazard ratio = 8.49, 95%CI: 1.76-40.90; *P* = 0.008) maintained a positive impact on OS.

**DISCUSSION**

The present analysis reported the most extensive case series, to our knowledge, treated with the TKI pazopanib as first-line systemic therapy for advanced nccRCC patients.

The activity and efficacy outcomes are in line with those reported by two prior series from the literature, with an ORR around 27%, a good DCR (over 80%), an mPFS over 1 year, and a good mOS of 27.7 mo. Compared to the other older reports, our study also included patients receiving new-generation drugs as second-line after pazopanib (*i.e.*, nivolumab or cabozantinib), suggesting (in the univariate analysis) this choice as significantly associated with improved survival and providing some evidence for these treatment sequences in nccRCC.

Regarding safety, pazopanib was generally well-tolerated, with G3 TRAEs occurring only in 20% of patients and no G4-5 toxicities. The AE-related discontinuations and the initial dose reductions were relatively frequent. Still, no impact on the outcome was evidenced for the latter choice, often preferable for frail patients with hepatic impairment or cardiovascular comorbidities.

The limitations of our report are represented by the retrospective nature, the heterogeneous follow-up time (with a wide range, but a good median value), the lack of central independent revision for the histological samples (nccRCC histology based on the original diagnosis), and the limited number of patients receiving new-generation drugs (such as cabozantinib or nivolumab) in other treatment lines. On the other hand, the present analysis corroborates with the largest sample size two previous similar retrospective case series, providing herein clean data for pure first-line setting (as a difference *vs* Matrana *et al*[12]), and supporting the use of pazopanib as a single agent for nccRCC patients with advanced disease.

A further single-TKI alternative could be available in the next future as a primary choice for the subgroup of pRCC patients, represented by the third generation TKI cabozantinib. Currently approved as a first-line treatment option for ccRCC patients with poor- or intermediate-risk according to the IMDC model, this drug was investigated in a prospective study as a first- or second-line TKI for advanced pRCC. It demonstrated improved PFS (median 9.0 mo, 95%CI: 6-12) *vs* the comparator sunitinib (5.6 mo, 95%CI: 3-7; HR = 0.60, 95%CI: 0.37-0.97, *P* = 0.019) and ORR (23% *vs* 4% for sunitinib, *P* = 0.010), at the cost of quite manageable toxicity and a toxic death reported[15].

Beyond TKIs, the advent of immunotherapy has finally landed also in the field of nccRCC, reporting initial findings from prospective monotherapy trials. The single-arm phase II Keynote-427 trial investigated the efficacy and safety of single-agent pembrolizumab, a PD-1 inhibitor, in advanced nccRCC. In this study, 71.5% of patients had confirmed pRCC, 12.7% had chRCC, and 15.8% had unclassified RCC histology. Overall, the ORR was 26.7% (28.8% for papillary, 9.5% for chromophobe, and 30.8% for unclassified RCC); the mPFS was 4.2 mo (95%CI: 2.9-5.6), and the mOS was 28.9 mo. The toxicity was manageable, with 69.7% of patients reporting TRAEs; nevertheless, two deaths were reported as treatment-related[16]. These findings are pretty encouraging about the activity of immunotherapy in variant histologies. Anyway, the activity seems in line with those reported herein for pazopanib (similar ORR). In contrast, the efficacy appears relatively poor in terms of mPFS compared with that reported with TKIs in ours and similar populations. On the other hand, the OS outcome was similar.

Another first-line trial (Checkmate-920) recently investigated an immunotherapy combining ipilimumab and nivolumab (anti-CTLA-4 and anti-PD1 respectively) in a nccRCC treatment-naïve population. The first results reported relatively high rates of G3 (92.3%) and G4 (36.5%) toxicities (but without toxic deaths), ORR of 19.6%, and mPFS of 3.7 mo (95%CI: 2.7-4.6)[17]. The SUNNIFORECAST trial, a phase II randomized study currently ongoing with the same combination *vs* standard of care for previously untreated nccRCC patients, will provide further evidence about this exclusive immunotherapy strategy (NCT03075423).

**CONCLUSION**

On the one hand, RCC with sarcomatoid features (irrespective of the primary histology) indeed gains excellent benefit from immunotherapy compared to TKIs[18]. On the other hand, RCC with variant histology still needs a TKI-based approach, with new generation TKIs, possibly combined with ICIs in future trials.

Meanwhile, the single-agent options should include pazopanib, favored by excellent manageability in terms of safety, and supported by high feasibility and excellent cost-effectiveness, especially for elderly patients.

**ARTICLE HIGHLIGHTS**

***Research background***

Non-clear cell metastatic renal-cell carcinoma (nccRCC) has dismal results with standard systemic therapies and a generally worse prognosis when compared to its clear-cell counterpart.

***Research motivation***

We aimed to provide a piece of real-life evidence on the use of pazopanib in this patient subgroup.

***Research objectives***

To assess the activity, efficacy, and safety of pazopanib as first-line therapy for advanced nccRCC patients treated in a real-life setting.

***Research methods***

This was a multicenter retrospective observational analysis.

***Research results***

The objective response rate with pazopanib was 27.1%, the disease control rate was 83.3%, and the median progression-free survival and overall survival were 12.3 (95%CI: 3.6-20.9) mo and 27.7 (95%CI: 18.2-37.1) mo, respectively. Grade 3 adverse events occurred in 20% of patients, and no grade 4 or 5 toxicities were found.

***Research conclusions***

Pazopanib should be considered as a good first-line option for metastatic RCC with variant histology.

***Research perspectives***

Pazopanib warrants further development in metastatic RCC with variant histology.

**REFERENCES**

1 **Signoretti S**, Flaifel A, Chen YB, Reuter VE. Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers. *J Clin Oncol* 2018: JCO2018792259 [PMID: 30372384 DOI: 10.1200/JCO.2018.79.2259]

2 **Kroeger N**, Xie W, Lee JL, Bjarnason GA, Knox JJ, Mackenzie MJ, Wood L, Srinivas S, Vaishamayan UN, Rha SY, Pal SK, Yuasa T, Donskov F, Agarwal N, Kollmannsberger CK, Tan MH, North SA, Rini BI, Choueiri TK, Heng DY. Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria. *Cancer* 2013; **119**: 2999-3006 [PMID: 23696129 DOI: 10.1002/cncr.28151]

3 **Motzer R**, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Kopyltsov E, Méndez-Vidal MJ, Kozlov V, Alyasova A, Hong SH, Kapoor A, Alonso Gordoa T, Merchan JR, Winquist E, Maroto P, Goh JC, Kim M, Gurney H, Patel V, Peer A, Procopio G, Takagi T, Melichar B, Rolland F, De Giorgi U, Wong S, Bedke J, Schmidinger M, Dutcus CE, Smith AD, Dutta L, Mody K, Perini RF, Xing D, Choueiri TK; CLEAR Trial Investigators. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. *N Engl J Med* 2021; **384**: 1289-1300 [PMID: 33616314 DOI: 10.1056/NEJMoa2035716]

4 **Choueiri TK,** Powles T, Burotto M, Bourlon MT, Zurawski B, Oyervides Juárez VM, Hsieh JJ, Basso U, Shah AY, Suarez C, Hamzaj A, Barrios CH, Richardet M, Pook D, Tomita Y, Escudier B, Zhang J, Simsek B, Apolo AB, Motzer RJ. Nivolumab + cabozantinib vs. sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial. *Ann Oncol* 2020; **31** (suppl\_4): S1142-S1215

5 **Rini BI**, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang YH, Tamada S, Shou Q, Perini RF, Chen M, Atkins MB, Powles T; KEYNOTE-426 Investigators. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. *N Engl J Med* 2019; **380**: 1116-1127 [PMID: 30779529 DOI: 10.1056/NEJMoa1816714]

6 **Motzer RJ**, Rini BI, McDermott DF, Arén Frontera O, Hammers HJ, Carducci MA, Salman P, Escudier B, Beuselinck B, Amin A, Porta C, George S, Neiman V, Bracarda S, Tykodi SS, Barthélémy P, Leibowitz-Amit R, Plimack ER, Oosting SF, Redman B, Melichar B, Powles T, Nathan P, Oudard S, Pook D, Choueiri TK, Donskov F, Grimm MO, Gurney H, Heng DYC, Kollmannsberger CK, Harrison MR, Tomita Y, Duran I, Grünwald V, McHenry MB, Mekan S, Tannir NM; CheckMate 214 investigators. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. *Lancet Oncol* 2019; **20**: 1370-1385 [PMID: 31427204 DOI: 10.1016/S1470-2045(19)30413-9]

7 **Tannir NM**, Jonasch E, Albiges L, Altinmakas E, Ng CS, Matin SF, Wang X, Qiao W, Dubauskas Lim Z, Tamboli P, Rao P, Sircar K, Karam JA, McDermott DF, Wood CG, Choueiri TK. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. *Eur Urol* 2016; **69**: 866-874 [PMID: 26626617 DOI: 10.1016/j.eururo.2015.10.049]

8 **Armstrong AJ**, Halabi S, Eisen T, Broderick S, Stadler WM, Jones RJ, Garcia JA, Vaishampayan UN, Picus J, Hawkins RE, Hainsworth JD, Kollmannsberger CK, Logan TF, Puzanov I, Pickering LM, Ryan CW, Protheroe A, Lusk CM, Oberg S, George DJ. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. *Lancet Oncol* 2016; **17**: 378-388 [PMID: 26794930 DOI: 10.1016/S1470-2045(15)00515-X]

9 **Motzer RJ**, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, Boleti E, Fife K, Jin J, Jones R, Uemura H, De Giorgi U, Harmenberg U, Wang J, Sternberg CN, Deen K, McCann L, Hackshaw MD, Crescenzo R, Pandite LN, Choueiri TK. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. *N Engl J Med* 2013; **369**: 722-731 [PMID: 23964934 DOI: 10.1056/NEJMoa1303989]

10 **Escudier B**, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, Gschwend JE, De Giorgi U, Parikh O, Hawkins R, Sevin E, Négrier S, Khan S, Diaz J, Redhu S, Mehmud F, Cella D. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. *J Clin Oncol* 2014; **32**: 1412-1418 [PMID: 24687826 DOI: 10.1200/JCO.2013.50.8267]

11 **Buti S**, Bersanelli M, Maines F, Facchini G, Gelsomino F, Zustovich F, Santoni M, Verri E, De Giorgi U, Masini C, Morelli F, Vitale MG, Sava T, Prati G, Librici C, Fraccon AP, Fornarini G, Maruzzo M, Leonardi F, Caffo O. First-Line PAzopanib in NOn-clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study. *Clin Genitourin Cancer* 2017; **15**: e609-e614 [PMID: 28108284 DOI: 10.1016/j.clgc.2016.12.024]

12 **Matrana MR**, Baiomy A, Campbell M, Alamri S, Shetty A, Teegavarapu P, Kalra S, Xiao L, Atkinson B, Corn P, Jonasch E, Elsayes KM, Tannir NM. Outcomes of Patients With Metastatic Non-Clear-Cell Renal Cell Carcinoma Treated With Pazopanib. *Clin Genitourin Cancer* 2017; **15**: e205-e208 [PMID: 27568124 DOI: 10.1016/j.clgc.2016.07.016]

13 **Eisenhauer EA**, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer* 2009; **45**: 228-247 [PMID: 19097774 DOI: 10.1016/j.ejca.2008.10.026]

14 **U.S. Department of Health and Human Services.** Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 Published: June 14, 2010. Available from: https://www.eortc.be/services/doc/ctc/ctcae\_4.03\_2010-06-14\_quickrefe

15 **Pal SK**, Tangen C, Thompson IM Jr, Balzer-Haas N, George DJ, Heng DYC, Shuch B, Stein M, Tretiakova M, Humphrey P, Adeniran A, Narayan V, Bjarnason GA, Vaishampayan U, Alva A, Zhang T, Cole S, Plets M, Wright J, Lara PN Jr. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. *Lancet* 2021; **397**: 695-703 [PMID: 33592176 DOI: 10.1016/S0140-6736(21)00152-5]

16 **McDermott DF**, Lee JL, Ziobro M, Suarez C, Langiewicz P, Matveev VB, Wiechno P, Gafanov RA, Tomczak P, Pouliot F, Donskov F, Alekseev BY, Shin SJ, Bjarnason GA, Castellano D, Silverman RK, Perini RF, Schloss C, Atkins MB. Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma. *J Clin Oncol* 2021; **39**: 1029-1039 [PMID: 33529058 DOI: 10.1200/JCO.20.02365]

17 **Emamekhoo H,** Olsen M, Carthon BC, Drakaki A, Tykodi SS. Safety and efficacy of nivolumab plus ipilimumab (NIVO+IPI) in patients with advanced renal cell carcinoma (aRCC) with brain metastases: Interim analysis of CheckMate 920. *J Clin Oncol* 2019; **37**: 4517-4517

18 **Iacovelli R**, Ciccarese C, Bria E, Bracarda S, Porta C, Procopio G, Tortora G. Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors. *Eur J Cancer* 2020; **136**: 195-203 [PMID: 32712550 DOI: 10.1016/j.ejca.2020.06.008]

**Footnotes**

**Institutional review board statement:** The study was reviewed and approved by the Local Ethics Committee of Parma (Italy).

**Informed consent statement:** All study participants provided informed written consent prior to study enrollment.

**Conflict-of-interest statement:** Melissa Bersanelli received honoraria as a speaker at scientific events by Bristol-Myers Squibb (BMS), Novartis, Astra Zeneca, Pierre Fabre, and Pfizer and as a consultant for advisory role by Novartis, BMS, IPSEN, and Pfizer; she also received fees for copyright transfer by Sciclone Pharmaceuticals and research funding by Roche S.p.A., Seqirus UK, Pfizer, Novartis, BMS, Astra Zeneca, and Sanofi Genzyme. Sebastiano Buti received honoraria as a speaker at scientific events and advisory role by Bristol-Myers Squibb (BMS), Pfizer; MSD, Ipsen, Roche, Eli-Lilly, AstraZeneca, and Novartis; he also received research funding from Novartis. Orazio Caffo received honoraria as a speaker by Astellas, Bayer, Astra Zeneca, Janssen, Pfizer, Sanofi, and a consultant for advisory role by Astellas, Janssen, MSD. Camillo Porta received honoraria a Consultant or Speaker for Angelini, Astra Zeneca, BMS, Eisai, EUSA, General Electric, Ipsen, Janssen, Merck, MSD, Novartis and Pfizer, acted as an Expert Testimony for EUSA and Pfizer and was a Protocol Steering Committee Member ofr BMS, Eisai, and EUSA. Finally, he did receive travel support from Roche. All other authors have no conflict of interest to declare.

**Data sharing statement:** Data will be made available upon reasonable request by the corresponding author.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** February 27, 2021

**First decision:** May 4, 2021

**Article in press:**

**Specialty type:** Oncology

**Country/Territory of origin:** Italy

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Watanabe D **S-Editor:** Gong ZM **L-Editor:** Wang TQ **P-Editor:**

**Figure Legends**

A



B



**Figure 1 Progression-free survival (A) and overall survival (B) of the study population.**

**Table 1 Characteristics of patients, *n* (%)**

|  |  |
| --- | --- |
| **Baseline characteristic** | ***n* = 48** |
| Age, median (range) | 70 (27-86) |
| Sex |  |
| Males  | 36 (75) |
| Females | 12 (25) |
| Histology |  |
| Papillary | 24 (50) |
| Chromophobe | 9 (10.8) |
| Xp11 translocation | 1 (2.1) |
| Unclassified | 6 (12.5) |
| Mixed1 | 8 (16.7) |
| Grade (Fuhrman/ISUP) |  |
| 1-2 | 6 (12.5) |
| 3 | 15 (31.3) |
| 4 | 4 (8.3) |
| NA | 23 (47.9) |
| Stage at diagnosis |  |
| I-III | 33 (68.8) |
| IV | 15 (31.3) |
| Previous nephrectomy |  |
| Yes | 41 (85.4) |
| No | 7 (14.6) |
| Metastasectomy |  |
| Yes | 7 (14.6) |
| No | 41 (85.4) |
| ECOG PS |  |
| 0 | 37 (77.1) |
| 1 | 11 (22.9) |
| IMDC score risk group |  |
| Good | 19 (39.6) |
| Intermediate | 25 (52.1) |
| Poor | 2 (4.2) |
| NA | 2 (4.2) |
| Starting dose of pazopanib |  |
| 800 mg | 31(64.6) |
| 600 mg | 10 (20.8) |
| 400 mg | 7 (14.6) |

1Four tumors had mixed histology (clear-cell/papillary) with papillary histology prevalence and four tumors had mixed histology (clear-cell/chromophobe) with chromophobe histology prevalence. NA: not assessed/available; IMDC: International Metastatic Renal Cell Carcinoma Database Consortium; ECOG PS: Eastern Cooperative Oncology Group Performance Status; ISUP: International Society of Urological Pathology.

**Table 2 Adverse events according to Common Terminology Criteria for Adverse Events (version 4.0)**

|  |  |  |
| --- | --- | --- |
| **Adverse event** | **Grade 1/2, *n* (%)** | **Grade 3, *n* (%)** |
| Fatigue | 24 (50.0) |  |
| Diarrhea | 15 (31.3) | 2 (4.2) |
| Mucositis | 9 (18.8) |  |
| Hypertransaminasemia | 7 (14.6) | 4 (8.3) |
| Thrombocytopenia | 6 (12.5) |  |
| Anemia | 15 (31.2) | 2 (4.2) |
| Neutropenia | 5 (10.4) |  |
| Hypothyroidism | 15 (31.3) |  |
| Disgeusia | 5 (10.4) | 1 (2.1) |
| Cutaneous toxicity1 | 8 (16.7) |  |
| Nausea/vomiting | 14 (29.2) |  |
| Heart failure | 1 (2.1) |  |
| Renal failure | 5 (10.4) | 1 (2.1) |
| Other2 | 16 (33.3) |  |

1Including discoloration of hairs and cutis, hand-foot syndrome, and dermatitis. 2Including bleeding, sleepiness, hypertrigliceridemia, hypophosphoremia, hyperbilirubinemia, loss of appetite/hyporexia, dyspepsia/epigastralgia, and hypertension.

**Table 3 Objective response rate, progression-free survival, and overall survival outcomes**

|  |  |  |  |
| --- | --- | --- | --- |
| **Effectiveness outcome** | **All patients (*n* = 48)** | **Papillary RCC (*n* = 24)** | **Chromophobe RCC (*n* = 9)** |
| Response rate (RECIST 1.1), *n* (%) |  |  |  |
| Partial responses | 13 (27.1) | 6 (25.0) | 2 (22.2) |
| Complete responses | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Stable disease | 27 (56.3) | 14 (58.3) | 5 (55.5) |
| Progressions of disease | 6 (12.5) | 3 (12.5) | 1 (11.1) |
| Not evaluable | 2 (4.2) | 1 (4.2) | 1 (11.1) |
| Disease control rate | 40 (83.3)  | 20 (83.3) | 7 (77.8) |
| PFS |  |  |  |
| Median (mo) (95%CI) | 12.3 (3.6-20.9) | - | - |
| Rate of patients progression free at 6 mo | 67.8% | - | - |
| Rate of patients progression free at 12 mo | 49.0% | - | - |
| OS |  |  |  |
| Median (mo) (95%CI) | 27.6 (18.3-37.1)  | - | - |
| Rate of patients alive at 12 mo | 82.7% | - | - |
| Rate of patients alive at 24 mo | 62.0% | - | - |

RCC: Renal cell carcinoma; PFS: Progression free survival; OS: Overall survival; RECIST 1.1: Response Evaluation Criteria in Solid Tumours version 1.1.